2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

Thomas R. Collins is a medical writer based in Florida.

References

1. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24;353(21):2219–2228.
2. Appel GB, Conteras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103–1112.
3. Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2014 Dec 30. [Epub ahead of print]
4. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18–26.
5. Dall’Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015 May 20;2(1):e000089. eCollection 2015.
6. Korbet SM, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: The predictive value of a ≥ 50% reduction in proteinuria at 6 months. Nephrol Dial Transplant. 2013 Sep;28(9):2313–2318.
7. Wang NH, Zhu XY, Zhu Y. The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clin Immunol. 2015 Oct;160(2):342–348.
8. Niioka T, Komatsuda A, Kato S, et al. Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis. Xenobiotica. 2015 Dec;45(12):1147–1153.